• Moderna published its ESMO investor presentation on individualized cancer immunotherapy, including Phase 3 INTerpath-001 melanoma results.
• INTerpath-001 compared intismeran autogene with pembrolizumab against pembrolizumab alone as adjuvant treatment for resected stage IIB-IV melanoma.
• The presentation reported a recurrence-free survival benefit maintained through five years of follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.